Vericel Q4 2025 total revenue $92.9M (+23% YoY); FY25 net income up 59% to $16.5M

Vericel Corp

2025-FY EPS reported $0.32 revenue$276,259,000

Q4 total revenue $92.9M (+23% YoY); MACI revenue $84.1M (+23%); burn care $8.8M.
FY25 total revenue $276.3M (+16%); MACI revenue $239.5M (+21%); net income $16.5M ($0.32 diluted EPS).
Q4 adjusted EBITDA $37.3M (40% margin); FY25 adjusted EBITDA $70.9M (26% margin).
FY26 guidance: total revenue $316-326M, MACI revenue $280-286M, gross margin ~75%, adj. EBITDA margin ~27%.
Record Q4 MACI implants, biopsies, and implanting surgeons; MACI sales force expansion completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.